Ranbaxy debuts generic Lipitor in Germany, ahead of patent expiry

7 March 2012

The German subsidiary of India’s Ranbaxy Laboratories (AB: BO), Basics GmbH located in Leverkusen, yesterday launched Atorvastatin Basics (10/20/40/80 mg), a generic version of the cholesterol lowering drug Sortis, in the German market.

Ranbaxy, which is majority owned by Japan’s Daiichi Sankyo (TYO: 4568), had obtained, pursuant to a settlement agreement with Pfizer, the rights to an early entry of atorvastatin in the German market. Pfizer's patent for Sortis expires in Germany on May 7, 2012. Atorvastatin is best known under the trade name Lipitor.

Basics' affiliate in Germany, Daiichi Sankyo Deutschland GmbH will assist in the launch. Daiichi Sankyo has a substantial reach amongst Cardiologists and Physicians, in the German market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK